Inflammation-Sensitive Plasma Proteins Are Associated With Future Weight Gain

Inflammation-Sensitive Plasma Proteins Are Associated With Future Weight Gain Gunnar Engström 1 , Bo Hedblad 1 , Lars Stavenow 2 , Peter Lind 2 , Lars Janzon 1 and Folke Lindgärde 3 1 Department of Community Medicine, Lund University, Malmö, Sweden 2 Department of Medicine, Lund University, Malmö, S...

Full description

Saved in:
Bibliographic Details
Published inDiabetes (New York, N.Y.) Vol. 52; no. 8; pp. 2097 - 2101
Main Authors ENGSTRÖM, Gunnar, HEDBLAD, Bo, STAVENOW, Lars, LIND, Peter, JANZON, Lars, LINDGÄRDE, Folke
Format Journal Article
LanguageEnglish
Published Alexandria, VA American Diabetes Association 01.08.2003
Subjects
Adult
Alcohol
alpha 1-Antitrypsin - metabolism
Biological and medical sciences
Blood pressure
Blood proteins
Cardiovascular disease
Cardiovascular diseases
Ceruloplasmin - metabolism
Clinical Medicine
Cohort Studies
Cross-Sectional Studies
Demographic aspects
Diabetes
Diabetes. Impaired glucose tolerance
Endocrine pancreas. Apud cells (diseases)
Endocrinology and Diabetes
Endocrinopathies
Endokrinologi och diabetes
Fibrinogen - metabolism
Follow-Up Studies
Fundamental and applied biological sciences. Psychology
Glucose
Haptoglobins - metabolism
Hemodynamics. Rheology
Homeostasis
Humans
Inflammation
Inflammation - blood
Inflammation - diagnosis
Inflammation - epidemiology
Insulin resistance
Klinisk medicin
Male
Medical and Health Sciences
Medical sciences
Medicin och hälsovetenskap
Metabolic syndrome
Middle Aged
Obesity
Obesity - blood
Obesity - diagnosis
Obesity - epidemiology
Orosomucoid - metabolism
Physiological aspects
Plasma
Predictive Value of Tests
Proteins
Questionnaires
Risk Factors
Statistics
Tumor necrosis factor-TNF
Vertebrates: cardiovascular system
Weight gain
Weight Gain - physiology
Sweden
Endocrinopathy
Inflammation
Weight gain
Diabetes mellitus
Protein
Online AccessGet full text

Cover

Abstract Inflammation-Sensitive Plasma Proteins Are Associated With Future Weight Gain Gunnar Engström 1 , Bo Hedblad 1 , Lars Stavenow 2 , Peter Lind 2 , Lars Janzon 1 and Folke Lindgärde 3 1 Department of Community Medicine, Lund University, Malmö, Sweden 2 Department of Medicine, Lund University, Malmö, Sweden 3 Department of Vascular Diseases, Lund University, Malmö, Sweden Address correspondence and reprint requests to Gunnar Engström, MD, Department of Community Medicine, Malmö University Hospital, S-20502 Malmö, Sweden. E-mail: gunnar.engstrom{at}smi.mas.lu.se Abstract Cross-sectional studies have associated obesity and other components of the so-called metabolic syndrome with low-grade inflammation. The temporal and causal relations of this association have not been fully explored. This study explored whether elevated levels of inflammation-sensitive plasma proteins (ISPs) (fibrinogen, orosomucoid, α1-antitrypsin, haptoglobin, and ceruloplasmin) are associated with future weight gain. Five ISPs were measured in 2,821 nondiabetic healthy men (38–50 years of age) who were reexamined after a mean follow-up of 6.1 years. Future weight gain was studied in relation to the number of elevated ISPs (i.e., in the top quartile). The proportion with a large weight gain (75th percentile ≥3.8 kg) was 21.0, 25.9, 26.8, and 28.3%, respectively, among men with none, one, two, and three or more ISPs in the top quartile ( P for trend 0.0005). This relation remained significant after adjustments for weight at baseline, follow-up time, height (at baseline and follow-up), physical inactivity (at baseline and follow-up), smoking (at baseline and follow-up), high alcohol consumption, and insulin resistance. The relations were largely similar for all individual ISPs. Elevated ISP levels predict a large weight gain in middle-aged men. This relation could contribute to the relation between inflammation, the metabolic syndrome, and cardiovascular disease. HPA, hypothalamic-pituitary-adrenal IL, interleukin ISP, inflammation-sensitive plasma protein TNF-α, tumor necrosis factor-α Footnotes Accepted May 13, 2003. Received March 11, 2003. DIABETES
AbstractList Cross-sectional studies have associated obesity and other components of the so-called metabolic syndrome with low-grade inflammation. The temporal and causal relations of this association have not been fully explored. This study explored whether elevated levels of inflammation-sensitive plasma proteins (ISPs) (fibrinogen, orosomucoid, α1-antitrypsin, haptoglobin, and ceruloplasmin) are associated with future weight gain. Five ISPs were measured in 2,821 nondiabetic healthy men (38-50 years of age) who were reexamined after a mean follow-up of 6.1 years. Future weight gain was studied in relation to the number of elevated ISPs (i.e., in the top quartile). The proportion with a large weight gain (75th percentile ≥ 3.8 kg) was 21.0, 25.9, 26.8, and 28.3%, respectively, among men with none, one, two, and three or more ISPs in the top quartile (P for trend 0.0005). This relation remained significant after adjustments for weight at baseline, follow-up time, height (at baseline and follow-up), physical inactivity (at baseline and follow-up), smoking (at baseline and follow-up), high alcohol consumption, and insulin resistance. The relations were largely similar for all individual ISPs. Elevated ISP levels predict a large weight gain in middle-aged men. This relation could contribute to the relation between inflammation, the metabolic syndrome, and cardiovascular disease.
Cross-sectional studies have associated obesity and other components of the so-called metabolic syndrome with low-grade inflammation. The temporal and causal relations of this association have not been fully explored. This study explored whether elevated levels of inflammation-sensitive plasma proteins (ISPs) (fibrinogen, orosomucoid, alpha1-antitrypsin, haptoglobin, and ceruloplasmin) are associated with future weight gain. Five ISPs were measured in 2,821 nondiabetic healthy men (38-50 years of age) who were reexamined after a mean follow-up of 6.1 years. Future weight gain was studied in relation to the number of elevated ISPs (i.e., in the top quartile). The proportion with a large weight gain (75th percentile >/= 3.8 kg) was 21.0, 25.9, 26.8, and 28.3%, respectively, among men with none, one, two, and three or more ISPs in the top quartile (P for trend 0.0005). This relation remained significant after adjustments for weight at baseline, follow-up time, height (at baseline and follow-up), physical inactivity (at baseline and follow-up), smoking (at baseline and follow-up), high alcohol consumption, and insulin resistance. The relations were largely similar for all individual ISPs. Elevated ISP levels predict a large weight gain in middle-aged men. This relation could contribute to the relation between inflammation, the metabolic syndrome, and cardiovascular disease.
Cross-sectional studies have associated obesity and other components of the so-called metabolic syndrome with low-grade inflammation. The temporal and causal relations of this association have not been fully explored. This study explored whether elevated levels of inflammation-sensitive plasma proteins (ISPs) (fibrinogen, orosomucoid, α1-antitrypsin, haptoglobin, and ceruloplasmin) are associated with future weight gain. Five ISPs were measured in 2,821 nondiabetic healthy men (38–50 years of age) who were reexamined after a mean follow-up of 6.1 years. Future weight gain was studied in relation to the number of elevated ISPs (i.e., in the top quartile). The proportion with a large weight gain (75th percentile ≥3.8 kg) was 21.0, 25.9, 26.8, and 28.3%, respectively, among men with none, one, two, and three or more ISPs in the top quartile (P for trend 0.0005). This relation remained significant after adjustments for weight at baseline, follow-up time, height (at baseline and follow-up), physical inactivity (at baseline and follow-up), smoking (at baseline and follow-up), high alcohol consumption, and insulin resistance. The relations were largely similar for all individual ISPs. Elevated ISP levels predict a large weight gain in middle-aged men. This relation could contribute to the relation between inflammation, the metabolic syndrome, and cardiovascular disease.
Cross-sectional studies have associated obesity and other components of the so-called metabolic syndrome with low-grade inflammation. The temporal and causal relations of this association have not been fully explored. This study explored whether elevated levels of inflammation-sensitive plasma proteins (ISPs) (fibrinogen, orosomucoid, [alpha]1-antitrypsin, haptoglobin, and ceruloplasmin) are associated with future weight gain. Five ISPs were measured in 2,821 nondiabetic healthy men (38-50 years of age) who were reexamined after a mean follow-up of 6.1 years. Future weight gain was studied in relation to the number of elevated ISPs (i.e., in the top quartile). The proportion with a large weight gain (75th percentile [greater than or equal to] 3.8 kg) was 21.0, 25.9, 26.8, and 28.3%, respectively, among men with none, one, two, and three or more ISPs in the top quartile (P for trend 0.0005). This relation remained significant after adjustments for weight at baseline, follow-up time, height (at baseline and follow-up), physical inactivity (at baseline and follow-up), smoking (at baseline and follow-up), high alcohol consumption, and insulin resistance. The relations were largely similar for all individual ISPs. Elevated ISP levels predict a large weight gain in middle-aged men. This relation could contribute to the relation between inflammation, the metabolic syndrome, and cardiovascular disease.
Cross-sectional studies have associated obesity and other components of the so-called metabolic syndrome with low-grade inflammation. The temporal and causal relations of this association have not been fully explored. This study explored whether elevated levels of inflammation-sensitive plasma proteins (ISPs) (fibrinogen, orosomucoid, {alpha}1-antitrypsin, haptoglobin, and ceruloplasmin) are associated with future weight gain. Five ISPs were measured in 2,821 nondiabetic healthy men (38–50 years of age) who were reexamined after a mean follow-up of 6.1 years. Future weight gain was studied in relation to the number of elevated ISPs (i.e., in the top quartile). The proportion with a large weight gain (75th percentile >=3.8 kg) was 21.0, 25.9, 26.8, and 28.3%, respectively, among men with none, one, two, and three or more ISPs in the top quartile (P for trend 0.0005). This relation remained significant after adjustments for weight at baseline, follow-up time, height (at baseline and follow-up), physical inactivity (at baseline and follow-up), smoking (at baseline and follow-up), high alcohol consumption, and insulin resistance. The relations were largely similar for all individual ISPs. Elevated ISP levels predict a large weight gain in middle-aged men. This relation could contribute to the relation between inflammation, the metabolic syndrome, and cardiovascular disease. Several cross-sectional studies have reported positive correlations between body fatness and inflammation-sensitive plasma proteins (ISPs) and other inflammatory markers (1–4). Weight reduction in obese subjects has been associated with reduced inflammation (5–7). It has been proposed that proinflammatory cytokines formed in the adipose tissue, e.g., interleukin (IL)-6 and tumor necrosis factor-{alpha} (TNF-{alpha}), increase the hepatic synthesis of ISPs (4,8–10). However, the temporal and causal relations between obesity and elevated ISPs are incompletely understood. Even though inflammation is mainly considered an effect of obesity or weight increase, it also has been suggested that there could be a reverse relation, i.e., that inflammation could promote weight gain (11). A 3-year follow-up of the Atherosclerosis Risk in Communities (ARIC) study reported that a large weight gain was more common in subjects with elevated fibrinogen, white blood cells, von Willebrand factor, or factor VIII, i.e., four putative markers of inflammation (12). The Malmö Preventive Study cohort includes ~6,000 men with data on five ISPs (fibrinogen, haptoglobin, {alpha}1-antitrypsin, orosomucoid, and ceruloplasmin). Previous studies from this cohort have shown cross-sectional relations between ISP levels and BMI, blood pressure, and insulin resistance (1,13,14). Follow-up studies have shown that these proteins are associated with an increased incidence of cardiovascular diseases and an increased incidence of high blood pressure (15,16). The present study sought to explore whether these proteins predicted weight gain over a mean follow-up of 6 years.
Inflammation-Sensitive Plasma Proteins Are Associated With Future Weight Gain Gunnar Engström 1 , Bo Hedblad 1 , Lars Stavenow 2 , Peter Lind 2 , Lars Janzon 1 and Folke Lindgärde 3 1 Department of Community Medicine, Lund University, Malmö, Sweden 2 Department of Medicine, Lund University, Malmö, Sweden 3 Department of Vascular Diseases, Lund University, Malmö, Sweden Address correspondence and reprint requests to Gunnar Engström, MD, Department of Community Medicine, Malmö University Hospital, S-20502 Malmö, Sweden. E-mail: gunnar.engstrom{at}smi.mas.lu.se Abstract Cross-sectional studies have associated obesity and other components of the so-called metabolic syndrome with low-grade inflammation. The temporal and causal relations of this association have not been fully explored. This study explored whether elevated levels of inflammation-sensitive plasma proteins (ISPs) (fibrinogen, orosomucoid, α1-antitrypsin, haptoglobin, and ceruloplasmin) are associated with future weight gain. Five ISPs were measured in 2,821 nondiabetic healthy men (38–50 years of age) who were reexamined after a mean follow-up of 6.1 years. Future weight gain was studied in relation to the number of elevated ISPs (i.e., in the top quartile). The proportion with a large weight gain (75th percentile ≥3.8 kg) was 21.0, 25.9, 26.8, and 28.3%, respectively, among men with none, one, two, and three or more ISPs in the top quartile ( P for trend 0.0005). This relation remained significant after adjustments for weight at baseline, follow-up time, height (at baseline and follow-up), physical inactivity (at baseline and follow-up), smoking (at baseline and follow-up), high alcohol consumption, and insulin resistance. The relations were largely similar for all individual ISPs. Elevated ISP levels predict a large weight gain in middle-aged men. This relation could contribute to the relation between inflammation, the metabolic syndrome, and cardiovascular disease. HPA, hypothalamic-pituitary-adrenal IL, interleukin ISP, inflammation-sensitive plasma protein TNF-α, tumor necrosis factor-α Footnotes Accepted May 13, 2003. Received March 11, 2003. DIABETES
Cross-sectional studies have associated obesity and other components of the so-called metabolic syndrome with low-grade inflammation. The temporal and causal relations of this association have not been fully explored. This study explored whether elevated levels of inflammation-sensitive plasma proteins (ISPs) (fibrinogen, orosomucoid, alpha1-antitrypsin, haptoglobin, and ceruloplasmin) are associated with future weight gain. Five ISPs were measured in 2,821 nondiabetic healthy men (38-50 years of age) who were reexamined after a mean follow-up of 6.1 years. Future weight gain was studied in relation to the number of elevated ISPs (i.e., in the top quartile). The proportion with a large weight gain (75th percentile >/= 3.8 kg) was 21.0, 25.9, 26.8, and 28.3%, respectively, among men with none, one, two, and three or more ISPs in the top quartile (P for trend 0.0005). This relation remained significant after adjustments for weight at baseline, follow-up time, height (at baseline and follow-up), physical inactivity (at baseline and follow-up), smoking (at baseline and follow-up), high alcohol consumption, and insulin resistance. The relations were largely similar for all individual ISPs. Elevated ISP levels predict a large weight gain in middle-aged men. This relation could contribute to the relation between inflammation, the metabolic syndrome, and cardiovascular disease.Cross-sectional studies have associated obesity and other components of the so-called metabolic syndrome with low-grade inflammation. The temporal and causal relations of this association have not been fully explored. This study explored whether elevated levels of inflammation-sensitive plasma proteins (ISPs) (fibrinogen, orosomucoid, alpha1-antitrypsin, haptoglobin, and ceruloplasmin) are associated with future weight gain. Five ISPs were measured in 2,821 nondiabetic healthy men (38-50 years of age) who were reexamined after a mean follow-up of 6.1 years. Future weight gain was studied in relation to the number of elevated ISPs (i.e., in the top quartile). The proportion with a large weight gain (75th percentile >/= 3.8 kg) was 21.0, 25.9, 26.8, and 28.3%, respectively, among men with none, one, two, and three or more ISPs in the top quartile (P for trend 0.0005). This relation remained significant after adjustments for weight at baseline, follow-up time, height (at baseline and follow-up), physical inactivity (at baseline and follow-up), smoking (at baseline and follow-up), high alcohol consumption, and insulin resistance. The relations were largely similar for all individual ISPs. Elevated ISP levels predict a large weight gain in middle-aged men. This relation could contribute to the relation between inflammation, the metabolic syndrome, and cardiovascular disease.
Audience Professional
Author Lars Stavenow
Gunnar Engström
Bo Hedblad
Folke Lindgärde
Lars Janzon
Peter Lind
Author_xml – sequence: 1
  givenname: Gunnar
  surname: ENGSTRÖM
  fullname: ENGSTRÖM, Gunnar
  organization: Department of Community Medicine, Lund University, Malmö, Sweden
– sequence: 2
  givenname: Bo
  surname: HEDBLAD
  fullname: HEDBLAD, Bo
  organization: Department of Community Medicine, Lund University, Malmö, Sweden
– sequence: 3
  givenname: Lars
  surname: STAVENOW
  fullname: STAVENOW, Lars
  organization: Department of Medicine, Lund University, Malmö, Sweden
– sequence: 4
  givenname: Peter
  surname: LIND
  fullname: LIND, Peter
  organization: Department of Medicine, Lund University, Malmö, Sweden
– sequence: 5
  givenname: Lars
  surname: JANZON
  fullname: JANZON, Lars
  organization: Department of Community Medicine, Lund University, Malmö, Sweden
– sequence: 6
  givenname: Folke
  surname: LINDGÄRDE
  fullname: LINDGÄRDE, Folke
  organization: Department of Vascular Diseases, Lund University, Malmö, Sweden
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15007494$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/12882928$$D View this record in MEDLINE/PubMed
https://lup.lub.lu.se/record/116949$$DView record from Swedish Publication Index
oai:portal.research.lu.se:publications/c093cda6-fada-46f7-94b9-124b90eb61f3$$DView record from Swedish Publication Index
BookMark eNqNk29r2zAQxs3oWP9sX2AvhhlsMIYzWbYl-2UIa1bIaGGF7p04yedERZYzSV63bz-1SVtSsjGEJBC_55HudHecHNjBYpK8zsmEFgX_1GqQGNBPKjqpJ5Q0_FlylDdFkxWUfz9IjgjJaZbzhh8mx95fE0JYHC-Sw5zWNW1ofZR8PbOdgb6HoAebfUPrddA_Mb0w4HtIL9wQUFufTh2mU-8HpSFgm17psEpPxzDG4yvUy1VI56Dty-R5B8bjq-1-klyefr6cfckW5_Oz2XSRKV6WIWO0ZbKuZKVaVrR12UCHJYFSEdLSGoFwJhkhWBPFgEhJK6kkiw_uOENKi5MENrb-BtejFGune3C_xQBarAcXwAiHHsGplTCj8CgiZbS6C9ILRZpCtcBEBy2IknVcNKVsRE7jSlCyvCviHYu_3mHGdZxy6_2fdu83dms3_BjRB9Frr9AYsDiMXvCiIiWrSATfPgGvh9HZmE1Bc1bysuEsQtkGWoJBoW03BAdqiRYdmFgknY7H05ywoqkIbyI_2cPH0WKv1V7Bhx1BZAL-CksYvRf1fLHLZvtYNRiDSxTx42fnu_ybbYSj7LF9yOx9UUbg3RYAr8B0DqzS_pGrCIlpKCNXbzjlBu8ddkLpcPfHMTptRE7EbZ-I-z4RFRW1uO2TKKVPpA_u_xJ93IhWseBvtMNHaA_9B7gBJeg
CODEN DIAEAZ
CitedBy_id crossref_primary_10_3390_nu13113853
crossref_primary_10_1292_jvms_70_379
crossref_primary_10_17826_cumj_1589090
crossref_primary_10_1158_1055_9965_EPI_07_0374
crossref_primary_10_1371_journal_pone_0055603
crossref_primary_10_1586_erc_09_166
crossref_primary_10_1038_ijo_2008_94
crossref_primary_10_1016_j_regpep_2012_06_009
crossref_primary_10_1111_j_1467_789X_2012_00995_x
crossref_primary_10_1016_j_ddmec_2005_08_014
crossref_primary_10_1210_clinem_dgac485
crossref_primary_10_37349_emed_2023_00140
crossref_primary_10_1093_ije_dyq121
crossref_primary_10_1093_jn_136_7_1935S
crossref_primary_10_1007_s00394_008_0738_3
crossref_primary_10_21101_cejph_a3896
crossref_primary_10_1002_ejhf_49
crossref_primary_10_1017_S0954422408138732
crossref_primary_10_1111_vcp_12468
crossref_primary_10_3390_ani2020243
crossref_primary_10_3389_fphys_2021_651732
crossref_primary_10_1007_s11920_019_1000_9
crossref_primary_10_1007_s00592_016_0903_8
crossref_primary_10_1152_ajpendo_90460_2008
crossref_primary_10_1016_j_cyto_2008_07_004
crossref_primary_10_1007_s00125_008_1132_7
crossref_primary_10_1016_j_vetimm_2012_03_011
crossref_primary_10_1161_01_STR_0000152328_66493_0a
crossref_primary_10_1024_0300_9831_a000648
crossref_primary_10_1038_oby_2007_352
crossref_primary_10_1017_S1368980021001713
crossref_primary_10_3390_ijerph16162854
crossref_primary_10_1007_s11033_019_05000_5
crossref_primary_10_1089_dia_2006_8_7
crossref_primary_10_1097_TA_0b013e3181a92ce0
crossref_primary_10_1007_s12032_014_0038_0
crossref_primary_10_1038_s41366_023_01335_z
crossref_primary_10_15436_2377_0619_19_2467
crossref_primary_10_1079_PNS2004406
crossref_primary_10_1161_01_ATV_0000116863_37311_82
crossref_primary_10_1002_oby_21833
crossref_primary_10_1016_j_crvi_2006_03_020
crossref_primary_10_3390_ijerph17217851
crossref_primary_10_1007_s00125_006_0381_6
crossref_primary_10_1053_j_jrn_2021_10_007
crossref_primary_10_1007_s00424_009_0693_8
crossref_primary_10_1108_NFS_09_2017_0203
crossref_primary_10_1016_j_physbeh_2007_11_052
crossref_primary_10_1152_ajpendo_00076_2004
crossref_primary_10_1016_j_ijhm_2014_01_009
crossref_primary_10_1016_j_numecd_2010_06_001
crossref_primary_10_4103_aam_aam_140_23
crossref_primary_10_1002_ddr_20137
crossref_primary_10_3390_nu14071409
crossref_primary_10_1093_ajh_hpw007
crossref_primary_10_1186_1471_2458_8_189
crossref_primary_10_1111_ijcp_14567
crossref_primary_10_1161_CIR_0000000000001185
crossref_primary_10_1016_j_physbeh_2008_03_010
crossref_primary_10_3109_03014460_2014_968619
crossref_primary_10_7243_2055_091X_4_7
crossref_primary_10_1371_journal_pone_0149436
crossref_primary_10_1016_j_genm_2012_01_002
crossref_primary_10_1038_oby_2010_73
crossref_primary_10_1007_s43188_023_00190_4
crossref_primary_10_1038_oby_2010_75
crossref_primary_10_2337_diabetes_55_01_06_db05_1108
crossref_primary_10_1186_s13104_020_05390_x
crossref_primary_10_1016_j_pneurobio_2012_06_006
crossref_primary_10_1007_s00125_005_0021_6
crossref_primary_10_1161_01_ATV_0000102924_11767_8D
crossref_primary_10_1155_2012_951093
crossref_primary_10_1161_CIRCULATIONAHA_108_191394
crossref_primary_10_1093_ehjcvp_pvv056
crossref_primary_10_1111_j_1365_201X_2005_01468_x
crossref_primary_10_1101_cshperspect_a021881
crossref_primary_10_1039_D4FO01088D
crossref_primary_10_1080_10408398_2011_594914
crossref_primary_10_1186_s13073_016_0271_6
crossref_primary_10_1371_journal_pone_0013341
crossref_primary_10_1186_1743_7075_6_40
crossref_primary_10_1007_s11695_010_0103_5
crossref_primary_10_1038_oby_2006_27
crossref_primary_10_1111_j_1398_9995_2007_01506_x
crossref_primary_10_1128_msystems_00964_21
crossref_primary_10_13005_bpj_2493
crossref_primary_10_1371_journal_pone_0121971
crossref_primary_10_20945_2359_3997000000631
crossref_primary_10_1371_journal_pmed_1003679
crossref_primary_10_1089_cell_2012_0091
crossref_primary_10_1097_HJH_0b013e32831e13e5
crossref_primary_10_1016_j_molmed_2018_03_005
crossref_primary_10_1016_j_nupar_2010_02_003
crossref_primary_10_1038_s41366_022_01101_7
crossref_primary_10_3923_pjn_2014_774_779
crossref_primary_10_1016_j_mehy_2010_11_013
crossref_primary_10_1111_ijpo_12588
crossref_primary_10_1586_eem_10_19
crossref_primary_10_1007_s10654_011_9565_6
crossref_primary_10_1186_1758_5996_5_31
crossref_primary_10_1016_j_mehy_2006_04_008
crossref_primary_10_17721_1728_2748_2019_77_21_26
crossref_primary_10_1016_j_clinbiochem_2011_01_014
crossref_primary_10_1038_sj_jhh_1002037
crossref_primary_10_1186_s12944_020_01364_x
crossref_primary_10_1093_ajcn_87_1_30
crossref_primary_10_1079_BJN20041213
crossref_primary_10_2217_17460875_1_1_81
crossref_primary_10_1016_j_metabol_2007_08_024
crossref_primary_10_3390_ijms20194905
crossref_primary_10_1007_s00424_007_0301_8
crossref_primary_10_1016_j_bjps_2008_12_021
crossref_primary_10_1080_02770903_2019_1571083
crossref_primary_10_3132_dvdr_2007_060
crossref_primary_10_1016_j_jad_2011_08_022
crossref_primary_10_3109_07853890_2013_857259
crossref_primary_10_1017_S0029665109990206
crossref_primary_10_3389_fendo_2023_1259854
crossref_primary_10_33808_clinexphealthsci_975706
crossref_primary_10_1007_BF03346317
crossref_primary_10_1186_s12902_022_01136_x
crossref_primary_10_1186_1758_5996_2_38
crossref_primary_10_2337_diabetes_54_4_917
crossref_primary_10_17352_ijpsdr_000006
crossref_primary_10_1159_000499961
crossref_primary_10_1016_j_cger_2011_03_005
crossref_primary_10_1016_j_numecd_2015_07_004
crossref_primary_10_1093_jnci_djh001
crossref_primary_10_1038_nutd_2011_16
crossref_primary_10_1186_s12884_022_04849_y
crossref_primary_10_1161_01_ATV_0000134293_31512_be
crossref_primary_10_3390_nu13051536
crossref_primary_10_1097_01_ta_0000200842_19740_38
crossref_primary_10_1038_sj_ijo_0803011
crossref_primary_10_1161_CIR_0b013e31821c7c64
crossref_primary_10_2337_diacare_29_03_06_dc05_0679
crossref_primary_10_1038_jhh_2010_92
crossref_primary_10_1002_dmrr_3377
crossref_primary_10_1017_S0007114511000468
crossref_primary_10_1016_j_neubiorev_2015_08_021
crossref_primary_10_1016_j_obmed_2023_100512
crossref_primary_10_3945_jn_114_203133
crossref_primary_10_1038_ijo_2009_27
crossref_primary_10_1042_BST0331078
crossref_primary_10_1016_j_physbeh_2007_10_010
crossref_primary_10_1515_tjb_2018_0152
crossref_primary_10_4081_pr_2010_e19
crossref_primary_10_1002_dmrr_433
crossref_primary_10_1038_s41416_018_0211_x
crossref_primary_10_1007_s11906_004_0014_8
crossref_primary_10_1038_sj_ijo_0803306
crossref_primary_10_1038_sj_ijo_0803702
crossref_primary_10_1039_C6BM00921B
crossref_primary_10_1097_MCO_0b013e32834d199f
crossref_primary_10_1186_scrt393
crossref_primary_10_1016_j_ijchy_2019_100012
crossref_primary_10_2337_diabetes_54_2_570
crossref_primary_10_1017_S0007114511001541
crossref_primary_10_1097_MOL_0b013e3283346ca2
crossref_primary_10_1016_j_annepidem_2006_03_005
crossref_primary_10_1177_0003319708314249
crossref_primary_10_1016_j_nutres_2009_01_006
crossref_primary_10_1016_j_bbrc_2005_09_068
crossref_primary_10_1016_j_nut_2009_09_020
crossref_primary_10_1016_j_domaniend_2012_04_004
crossref_primary_10_1093_ajcn_82_2_421
crossref_primary_10_1590_S1517_86922009000600012
crossref_primary_10_3109_08923970903104090
crossref_primary_10_1016_j_atherosclerosis_2008_05_038
crossref_primary_10_1016_j_jnutbio_2017_06_008
crossref_primary_10_36011_cpp_2021_3_e5
crossref_primary_10_1371_journal_pone_0090357
crossref_primary_10_1152_ajpendo_00251_2017
crossref_primary_10_1007_s40618_022_01815_5
crossref_primary_10_1016_j_atherosclerosis_2005_11_035
crossref_primary_10_1016_j_nut_2004_11_005
crossref_primary_10_1161_JAHA_116_003262
crossref_primary_10_3390_jcm8071053
crossref_primary_10_1161_CIRCHEARTFAILURE_108_827071
crossref_primary_10_23736_S0393_3660_20_04259_X
crossref_primary_10_1155_2013_363728
crossref_primary_10_1038_oby_2004_147
crossref_primary_10_1177_000331970505600501
Cites_doi 10.1161/01.ATV.0000041842.43905.F3
10.1016/S0021-9150(99)00463-3
10.1046/j.1365-2796.2003.01099.x
10.1046/j.1365-2796.1999.00490.x
10.1161/hc0502.103331
10.1093/ajcn/75.4.767
10.1093/ajcn/75.3.492
10.1056/NEJM199902113400607
10.1016/S0303-7207(02)00007-2
10.1007/BF00280883
10.1038/oby.2000.33
10.1210/jcem.83.8.5026
10.1079/PNS2001110
10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U
10.2337/diacare.23.6.831
10.1046/j.1467-789x.2001.00027.x
10.1210/jcem.85.8.6854
10.1016/S0165-5728(02)00357-0
10.2337/diabetes.52.2.442
10.1161/01.CIR.0000055014.62083.05
10.1111/j.1360-0443.1982.tb02459.x
10.1161/01.STR.0000034787.02925.1F
10.1016/S0899-9007(00)00449-4
10.2337/diacare.22.12.1971
10.1161/01.ATV.21.3.452
10.1053/meta.2002.31339
10.1161/01.ATV.19.4.972
10.3109/00365517209102748
10.1210/jc.86.1.355
10.1161/hy0302.104670
10.1079/PNS200194
10.1023/A:1012903330944
10.1007/s001250051058
10.2337/diabetes.51.4.1131
10.1038/sj.ijo.0801792
10.1016/S0899-9007(01)00672-4
10.1161/01.CIR.0000017327.69909.FF
10.1016/S0024-3205(99)00472-5
10.1097/00001648-200209000-00012
10.1210/jc.85.2.799
10.1046/j.1365-2796.2000.00568.x
10.1001/jama.286.3.327
ContentType Journal Article
Copyright 2004 INIST-CNRS
COPYRIGHT 2003 American Diabetes Association
COPYRIGHT 2003 American Diabetes Association
Copyright American Diabetes Association Aug 2003
Copyright_xml – notice: 2004 INIST-CNRS
– notice: COPYRIGHT 2003 American Diabetes Association
– notice: COPYRIGHT 2003 American Diabetes Association
– notice: Copyright American Diabetes Association Aug 2003
CorporateAuthor Lunds universitet
Department of Clinical Sciences, Malmö
Medicinska fakulteten
Lund University
Institutionen för kliniska vetenskaper, Malmö
Faculty of Medicine
CorporateAuthor_xml – name: Faculty of Medicine
– name: Medicinska fakulteten
– name: Institutionen för kliniska vetenskaper, Malmö
– name: Lund University
– name: Lunds universitet
– name: Department of Clinical Sciences, Malmö
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
8GL
3V.
7RV
7X7
7XB
88E
88I
8AF
8AO
8C1
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BEC
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
HCIFZ
K9-
K9.
KB0
LK8
M0R
M0S
M1P
M2O
M2P
M7P
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
S0X
7X8
ADTPV
AGCHP
AOWAS
D8T
D95
ZZAVC
DOI 10.2337/diabetes.52.8.2097
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: High School
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
STEM Database
ProQuest Pharma Collection
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
eLibrary
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
SciTech Premium Collection
Consumer Health Database
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Biological Sciences
Consumer Health Database
Health & Medical Collection (Alumni)
Medical Database
ProQuest Research Library
Science Database
Biological Science Database
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
SIRS Editorial
MEDLINE - Academic
SwePub
SWEPUB Lunds universitet full text
SwePub Articles
SWEPUB Freely available online
SWEPUB Lunds universitet
SwePub Articles full text
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
elibrary
ProQuest AP Science
SciTech Premium Collection
ProQuest Central China
ProQuest One Applied & Life Sciences
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest One Academic Middle East (New)
SIRS Editorial
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Research Library
ProQuest Public Health
ProQuest Central Basic
ProQuest Science Journals
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
ProQuest Medical Library
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
CrossRef



MEDLINE - Academic
Research Library Prep
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Statistics
EISSN 1939-327X
EndPage 2101
ExternalDocumentID oai_portal_research_lu_se_publications_c093cda6_fada_46f7_94b9_124b90eb61f3
oai_lup_lub_lu_se_c093cda6_fada_46f7_94b9_124b90eb61f3
384355081
A106395079
12882928
15007494
10_2337_diabetes_52_8_2097
diabetes_52_8_2097
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Sweden
GeographicLocations_xml – name: Sweden
GroupedDBID -
08R
0R
1AW
29F
2WC
3V.
4.4
53G
55
5GY
5RE
5RS
5VS
7RV
7X7
88E
88I
8AF
8AO
8C1
8F7
8FE
8FH
8FI
8FJ
8G5
8GL
8R4
8R5
AAQQT
AAWTL
AAYEP
AAYJJ
ABFLS
ABOCM
ABPTK
ABUWG
ACDCL
ACGOD
ACPRK
ADACO
ADBBV
ADBIT
AENEX
AFFNX
AFKRA
AHMBA
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BAWUL
BBAFP
BBNVY
BCR
BCU
BEC
BENPR
BES
BHPHI
BKEYQ
BKNYI
BLC
BPHCQ
BVXVI
C1A
CS3
DIK
DU5
DWQXO
E3Z
EBS
EDB
EJD
EX3
F5P
FRP
FYUFA
GICCO
GJ
GNUQQ
GUQSH
GX1
H13
HCIFZ
HZ
IAG
IAO
IEA
IHR
INH
INR
IOF
IPO
J5H
K-O
K9-
KM
KQ8
L7B
LK8
M0R
M1P
M2O
M2P
M2Q
M5
M7P
MBDVC
O0-
O9-
OB3
OBH
OK1
OVD
P2P
PADUT
PCD
PEA
PQEST
PQQKQ
PQUKI
PRINS
PROAC
PSQYO
Q2X
RHF
RHI
RPM
S0X
SJFOW
SJN
SV3
TDI
WH7
WOQ
WOW
X7M
XZ
ZA5
ZGI
ZXP
ZY1
---
.55
.GJ
.XZ
08P
0R~
18M
354
6PF
AAFWJ
AAKAS
AAYOK
AAYXX
ACGFO
ADZCM
AEGXH
AERZD
AIAGR
AIZAD
ALIPV
BTFSW
CCPQU
CITATION
EMOBN
HMCUK
HZ~
ITC
K2M
M5~
N4W
NAPCQ
OHH
PHGZM
PHGZT
TEORI
TR2
UKHRP
VVN
W8F
YFH
YHG
YOC
~KM
1CY
ADGHP
AI.
H~9
IQODW
MVM
O5R
O5S
PJZUB
PPXIY
PQGLB
VH1
XOL
YQJ
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7XB
8FK
K9.
PKEHL
Q9U
7X8
ADTPV
AGCHP
AOWAS
D8T
D95
ZZAVC
ID FETCH-LOGICAL-c744t-62d6b85b5cd63d849afe40a4c00d28ea076b600e80c6a0bb25bcb6292f76e223
IEDL.DBID 7X7
ISSN 0012-1797
1939-327X
IngestDate Thu Aug 21 06:53:32 EDT 2025
Thu Jul 03 05:17:38 EDT 2025
Thu Jul 10 18:57:41 EDT 2025
Fri Jul 25 10:55:38 EDT 2025
Fri Jun 13 00:48:39 EDT 2025
Tue Jun 10 21:25:55 EDT 2025
Fri Jun 27 03:57:58 EDT 2025
Tue Jun 10 20:04:07 EDT 2025
Fri May 23 03:14:19 EDT 2025
Mon Jul 21 09:11:50 EDT 2025
Thu Apr 24 22:59:38 EDT 2025
Tue Jul 01 03:03:48 EDT 2025
Fri Jan 15 19:45:53 EST 2021
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords Endocrinopathy
Inflammation
Weight gain
Diabetes mellitus
Protein
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c744t-62d6b85b5cd63d849afe40a4c00d28ea076b600e80c6a0bb25bcb6292f76e223
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://lup.lub.lu.se/record/116949
PMID 12882928
PQID 216474976
PQPubID 34443
PageCount 5
ParticipantIDs crossref_citationtrail_10_2337_diabetes_52_8_2097
proquest_journals_216474976
gale_incontextgauss_8GL_A106395079
pubmed_primary_12882928
gale_incontextcollege_GICCO_A106395079
swepub_primary_oai_portal_research_lu_se_publications_c093cda6_fada_46f7_94b9_124b90eb61f3
swepub_primary_oai_lup_lub_lu_se_c093cda6_fada_46f7_94b9_124b90eb61f3
gale_infotracacademiconefile_A106395079
proquest_miscellaneous_73504650
highwire_diabetes_diabetes_52_8_2097
pascalfrancis_primary_15007494
gale_infotracgeneralonefile_A106395079
crossref_primary_10_2337_diabetes_52_8_2097
ProviderPackageCode RHF
RHI
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2003-08-01
PublicationDateYYYYMMDD 2003-08-01
PublicationDate_xml – month: 08
  year: 2003
  text: 2003-08-01
  day: 01
PublicationDecade 2000
PublicationPlace Alexandria, VA
PublicationPlace_xml – name: Alexandria, VA
– name: United States
– name: New York
PublicationTitle Diabetes (New York, N.Y.)
PublicationTitleAlternate Diabetes
PublicationYear 2003
Publisher American Diabetes Association
Publisher_xml – name: American Diabetes Association
References 2022031209065235200_R10
2022031209065235200_R32
2022031209065235200_R11
2022031209065235200_R33
2022031209065235200_R12
2022031209065235200_R34
2022031209065235200_R13
2022031209065235200_R35
2022031209065235200_R30
2022031209065235200_R31
2022031209065235200_R18
2022031209065235200_R19
2022031209065235200_R14
2022031209065235200_R36
2022031209065235200_R15
2022031209065235200_R37
2022031209065235200_R16
2022031209065235200_R38
2022031209065235200_R17
2022031209065235200_R39
2022031209065235200_R9
2022031209065235200_R5
2022031209065235200_R6
2022031209065235200_R7
2022031209065235200_R8
2022031209065235200_R1
2022031209065235200_R21
2022031209065235200_R43
2022031209065235200_R2
2022031209065235200_R22
2022031209065235200_R3
2022031209065235200_R23
2022031209065235200_R4
2022031209065235200_R24
2022031209065235200_R40
2022031209065235200_R41
2022031209065235200_R20
2022031209065235200_R42
2022031209065235200_R29
2022031209065235200_R25
2022031209065235200_R26
2022031209065235200_R27
2022031209065235200_R28
References_xml – ident: 2022031209065235200_R18
– ident: 2022031209065235200_R16
  doi: 10.1161/01.ATV.0000041842.43905.F3
– ident: 2022031209065235200_R10
  doi: 10.1016/S0021-9150(99)00463-3
– ident: 2022031209065235200_R40
  doi: 10.1046/j.1365-2796.2003.01099.x
– ident: 2022031209065235200_R28
  doi: 10.1046/j.1365-2796.1999.00490.x
– ident: 2022031209065235200_R7
  doi: 10.1161/hc0502.103331
– ident: 2022031209065235200_R23
  doi: 10.1093/ajcn/75.4.767
– ident: 2022031209065235200_R26
  doi: 10.1093/ajcn/75.3.492
– ident: 2022031209065235200_R33
  doi: 10.1056/NEJM199902113400607
– ident: 2022031209065235200_R35
  doi: 10.1016/S0303-7207(02)00007-2
– ident: 2022031209065235200_R19
  doi: 10.1007/BF00280883
– ident: 2022031209065235200_R12
  doi: 10.1038/oby.2000.33
– ident: 2022031209065235200_R5
  doi: 10.1210/jcem.83.8.5026
– ident: 2022031209065235200_R9
  doi: 10.1079/PNS2001110
– ident: 2022031209065235200_R32
  doi: 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U
– ident: 2022031209065235200_R37
  doi: 10.2337/diacare.23.6.831
– ident: 2022031209065235200_R38
  doi: 10.1046/j.1467-789x.2001.00027.x
– ident: 2022031209065235200_R24
  doi: 10.1210/jcem.85.8.6854
– ident: 2022031209065235200_R41
  doi: 10.1016/S0165-5728(02)00357-0
– ident: 2022031209065235200_R14
  doi: 10.2337/diabetes.52.2.442
– ident: 2022031209065235200_R27
  doi: 10.1161/01.CIR.0000055014.62083.05
– ident: 2022031209065235200_R20
  doi: 10.1111/j.1360-0443.1982.tb02459.x
– ident: 2022031209065235200_R13
  doi: 10.1161/01.STR.0000034787.02925.1F
– ident: 2022031209065235200_R36
  doi: 10.1016/S0899-9007(00)00449-4
– ident: 2022031209065235200_R3
  doi: 10.2337/diacare.22.12.1971
– ident: 2022031209065235200_R1
  doi: 10.1161/01.ATV.21.3.452
– ident: 2022031209065235200_R34
  doi: 10.1053/meta.2002.31339
– ident: 2022031209065235200_R4
  doi: 10.1161/01.ATV.19.4.972
– ident: 2022031209065235200_R21
  doi: 10.3109/00365517209102748
– ident: 2022031209065235200_R6
  doi: 10.1210/jc.86.1.355
– ident: 2022031209065235200_R25
  doi: 10.1161/hy0302.104670
– ident: 2022031209065235200_R8
  doi: 10.1079/PNS200194
– ident: 2022031209065235200_R39
  doi: 10.1023/A:1012903330944
– ident: 2022031209065235200_R29
  doi: 10.1007/s001250051058
– ident: 2022031209065235200_R31
  doi: 10.2337/diabetes.51.4.1131
– ident: 2022031209065235200_R2
  doi: 10.1038/sj.ijo.0801792
– ident: 2022031209065235200_R11
  doi: 10.1016/S0899-9007(01)00672-4
– ident: 2022031209065235200_R15
  doi: 10.1161/01.CIR.0000017327.69909.FF
– ident: 2022031209065235200_R43
  doi: 10.1016/S0024-3205(99)00472-5
– ident: 2022031209065235200_R22
  doi: 10.1097/00001648-200209000-00012
– ident: 2022031209065235200_R42
  doi: 10.1210/jc.85.2.799
– ident: 2022031209065235200_R17
  doi: 10.1046/j.1365-2796.2000.00568.x
– ident: 2022031209065235200_R30
  doi: 10.1001/jama.286.3.327
SSID ssj0006060
Score 2.2301798
Snippet Inflammation-Sensitive Plasma Proteins Are Associated With Future Weight Gain Gunnar Engström 1 , Bo Hedblad 1 , Lars Stavenow 2 , Peter Lind 2 , Lars Janzon 1...
Cross-sectional studies have associated obesity and other components of the so-called metabolic syndrome with low-grade inflammation. The temporal and causal...
SourceID swepub
proquest
gale
pubmed
pascalfrancis
crossref
highwire
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2097
SubjectTerms Adult
Alcohol
alpha 1-Antitrypsin - metabolism
Biological and medical sciences
Blood pressure
Blood proteins
Cardiovascular disease
Cardiovascular diseases
Ceruloplasmin - metabolism
Clinical Medicine
Cohort Studies
Cross-Sectional Studies
Demographic aspects
Diabetes
Diabetes. Impaired glucose tolerance
Endocrine pancreas. Apud cells (diseases)
Endocrinology and Diabetes
Endocrinopathies
Endokrinologi och diabetes
Fibrinogen - metabolism
Follow-Up Studies
Fundamental and applied biological sciences. Psychology
Glucose
Haptoglobins - metabolism
Hemodynamics. Rheology
Homeostasis
Humans
Inflammation
Inflammation - blood
Inflammation - diagnosis
Inflammation - epidemiology
Insulin resistance
Klinisk medicin
Male
Medical and Health Sciences
Medical sciences
Medicin och hälsovetenskap
Metabolic syndrome
Middle Aged
Obesity
Obesity - blood
Obesity - diagnosis
Obesity - epidemiology
Orosomucoid - metabolism
Physiological aspects
Plasma
Predictive Value of Tests
Proteins
Questionnaires
Risk Factors
Statistics
Tumor necrosis factor-TNF
Vertebrates: cardiovascular system
Weight gain
Weight Gain - physiology
Title Inflammation-Sensitive Plasma Proteins Are Associated With Future Weight Gain
URI http://diabetes.diabetesjournals.org/content/52/8/2097.abstract
https://www.ncbi.nlm.nih.gov/pubmed/12882928
https://www.proquest.com/docview/216474976
https://www.proquest.com/docview/73504650
https://lup.lub.lu.se/record/116949
oai:portal.research.lu.se:publications/c093cda6-fada-46f7-94b9-124b90eb61f3
Volume 52
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdgkxAviG_CoERoGg8oW-LYTvyERtUxEB0IDanixbIdp0waaVla8e9zFzvtiqqJh-QlFyt3vpzvzuffEbJfFYZVDoIcZrRLmOYm0ToHXS5LWKw5q-uufdv4TJx-Z58mfBJqc9pQVtnbxM5QVzOLOfIjisBXDBbPd_PfCTaNws3V0EHjNtlF5DKs6Comq3grBd_cn0DJKKJwFv7MDM3z4qhPbB5yeogFXoj5dG1d6q1zDxmMFZO6BaHVvtvFNnf0H6zRbn06uU_uBccyPvaa8IDccs1Dcmccts4fkfHHpobZ9ycVkxbr1tHSxXNwn3_puMNruGjaWF-5WIc5c1WMedrYA4_Ef7o0ajzVF81jcn4yOh-eJqGXQmILxhaJoJUwJTfcViKvSiZ17ViqmU3TipZOp4Uw4Pu4MrVCp8ZQbqwRVNK6EDCV-ROy08wa94zEUnNuhcyklY4ZUcuM6zylmmfasprxiGS9IJUNOOPY7uJSQbyBwle98BWnqlQo_Ii8Xb0z9ygbN1If4PwohK9osD7G-hyLAoaHX9Rxhm4X-LkyIq83Cad62baq_PB5g-hNIKpn8J1Wh3MJwC1CY21QHmxQTj0w-DbC_V5z1p-_jY_BhlatWefo2UkWkb1ezVQwLa1a_QgRebV6CjYBN3p042bLVhU5Txm43hF56nVzPTKFiErSMiIjr6yrJwgzfrmcw2XgUq1TNpW5rbRQta60YqIulGRGwhhwT50RWZ1H5MeWcXzkqAJc1c8w3vxaHvq_Bn9-I_t75G5XWNkVY74gO4urpXsJDuLCDDozAPdymA3I7vvR2ddvfwHxC2nv
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGJwEviP-EwRahMR5QtsSxnfgBoTE2VtYOhDpp4sWyHbtMGmlZWk18Jz4k5zhpV1RNvOwhecnllLMv57vz-XcIbRaZIoWBIIcoaSIiqYqkTEGX8xwWa0qsrdu39Y_Z4Qn5fEpPV9Cf9iyMK6tsbWJtqIuRdjnyHeyArwgsnu_HvyLXNMptrrYdNLxWHJnflxCxVe-6H2F6X2N8sD_YO4yapgKRzgiZRAwXTOVUUV2wtMgJl9aQWBIdxwXOjYS4XoETYPJYMxkrhanSimGObcZAphTY3kKrJIVApoNWP-wff_02s_wQDPgjLwl2sJ-ZP6SD0zTbaTOp2xRvu4oyBzJ1ZSFsl4MWo9iVaMoKZsn69hrL_N9_wE3rBfHgPrrXeLLhrle9B2jFlA_R7X6zV_8I9bulBXXzRyOjyhXKO9MajsFf_ynDGiDirKxCeWFC2SiJKUKXGA490kl4Wedtw6E8Kx-jwU2M8xPUKUeleYZCLinVjCdcc0MUszyhMo2xpInUxBIaoKQdSKEbYHPXX-NcQIDjBl-0gy8oFrlwgx-gt7N3xh7W41rqLTc_wuFllK4gR_ukjgCB976I3cT5eeBY8wC9WiQcymlVifxTb4HoTUNkR_CdWjYHIUBah8W1QLm1QDn0SOTLCDdbzZl__jI51he0ai46da4kJwFaa9VMNLasErM_L0Abs6dghNzOkizNaFqJLKUxAV8_QE-9bs45YwjhOM4DtO-VdfbE4ZqfT8dwKbhEZYSOeaoLyYSVhRSE2UxwojjwgHtsFEtsGqDvS_j4UFU0-Fg_Gn7jK4nv_2L-_FrxN9Cdw0G_J3rd46M1dLeu6qwrQV-gzuRial6CdzpR641RCJG4YTP0Fwn2pVs
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkSouiDeh0EaolANKN3HsJD4gVPVBlz7gUKSqF8t27KVSyS7Nrir-GT-PmTjZ7aJVxaWH7CWzo4w9Hs-Mx98QslHmmpUWghymlY2Y4jpSKgVdLgrYrDlzrmnfdnySHXxnX8742RL5092FwbLKziY2hrocGsyR9ygCXzHYPHuurYr4trv_afQrwgZSeNDaddPwGnJof19D9FZ_7O_CVL-jdH_vdOcgahsMRCZnbBxltMx0wTU3ZZaWBRPKWRYrZuK4pIVVEONrcAhsEZtMxVpTro3OqKAuz0C-FNjeI_fzlCe4wvKzaagXQ1jgL78kFAFAc39dh6Zp3utyqlucbmFtGcJN3dgSu42hQyvGYk1Vw3w532hjkSf8D8xpszXuPyIPW5823PZK-Jgs2eoJWTluT-2fkuN-5UDx_CXJqMaSeTSy4Qg8958qbKAiLqo6VFc2VK262DLEFHHoMU_C6yaDGw7URfWMnN7FKD8ny9Wwsi9JKBTnJhOJMMIynTmRcJXGVPFEGeYYD0jSDaQ0LcQ5dtq4lBDq4ODLbvAlp7KQOPgB-TD9z8gDfNxKvYnzIxE5o0IlND69I0Hgna9yO0GPD1xsEZC384QDNalrWXw-miN63xK5IXynUe2VCJAWUbnmKDfnKAcek3wR4UanObPPXyTH2pxWzUTn6FQKFpDVTs1ka9VqOV2DAVmfvgVzhGdMqrLDSS1hMcQMvP6AvPC6OeNMIZgTtAjInlfW6RtEOL-cjODR8MjaShOL1JQqk06VSrLM5VIwLYAH_MZWZ4lLA3K-gI8PWmWLlPWj5Te6kQL_L-avbhV_nayA8ZFH_ZPDVfKgKe9sSkJfk-Xx1cS-ATd1rNcaixASeccW6C-rvagr
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inflammation-sensitive+plasma+proteins+are+associated+with+future+weight+gain&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=ENGSTR%C3%96M%2C+Gunnar&rft.au=HEDBLAD%2C+Bo&rft.au=STAVENOW%2C+Lars&rft.au=LIND%2C+Peter&rft.date=2003-08-01&rft.pub=American+Diabetes+Association&rft.issn=0012-1797&rft.volume=52&rft.issue=8&rft.spage=2097&rft.epage=2101&rft_id=info:doi/10.2337%2Fdiabetes.52.8.2097&rft.externalDBID=n%2Fa&rft.externalDocID=15007494
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon